



Stockholm, Sweden

Press release November 5, 2020

## Oncopeptides hosts a virtual capital markets day on November 30

STOCKHOLM — November 5, 2020 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announces that the company will arrange a virtual capital markets day for investors, analysts and journalists on November 30<sup>th</sup>, 2020. The program will be published on the company's website during the week of November 23 at: [www.oncopeptides.com/en/calendar/](http://www.oncopeptides.com/en/calendar/)

### Oncopeptides Virtual Capital Markets Day

14.00 – 16.00 CET (8:00am-10am ET) November 30th, 2020

#### The presenters during the Capital Market Day will be:

CEO **Marty J Duvall**, Oncopeptides,

CSO, **Jakob Lindberg**, Oncopeptides

CMO **Klaas Bakker**, Oncopeptides

Professor **Paul Richardson**, MD, Dana-Farber Cancer Institute, Boston

Associate Professor **Maria-Victoria Mateos**, MD, PhD, University Hospital, Salamanca

Assistant Professor **Joshua Richter**, MD, Icahn School of Medicine, Mount Sinai Hospital, New York

The webcast will be accessible at: <https://tv.streamfabriken.com/oncopeptides-cmd-2020>

#### For more information, please contact:

Rein Piir, Head of Investor Relations, Oncopeptides

E-mail: [rein.piir@oncopeptides.com](mailto:rein.piir@oncopeptides.com)

Cell phone: +46 70 853 72 92

The information was submitted for publication at 14.00 CET on November 5, 2020.

#### About Oncopeptides

Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The lead product candidate melflufen, is a first in class peptide-drug conjugate that targets aminopeptidases and rapidly releases alkylating agents into tumor cells. Melflufen is in development as a new treatment for the hematological malignancy multiple myeloma and is being tested in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Based on the results from the HORIZON study a New Drug Application has been submitted to the U.S. Food and Drug Administration, FDA, for accelerated approval of melflufen in combination with dexamethasone for treatment of adult patients with triple-class refractory multiple myeloma. The FDA, has granted the New Drug Application a priority review, with a PDUFA date of February 28, 2021. Oncopeptides' global Headquarters is in Stockholm, Sweden and the U.S. Headquarters is situated in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO. More information is available on [www.oncopeptides.com](http://www.oncopeptides.com).